Expertise in
15
conditions

Mariano P. Provencio

Manuel De Falla Street #1, 
Madrid, MD, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
15
conditions
Manuel De Falla Street #1, 
Madrid, MD, ES 

Overview

Mariano Provencio practices in Madrid, Spain. Mr. Provencio is highly rated in 15 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Follicular Lymphoma, EGFR Positive Lung Cancer, and Tissue Biopsy.

His clinical research consists of co-authoring 275 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Manuel De Falla Street #1, Madrid, MD 28222, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Diagnostic test
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Brigatinib
Study Phase: Phase 2
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Atezolizumab+Bevacizumab
Study Phase: Phase 2
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab
Study Phase: Phase 3
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Placlitaxel, Atezolizumab
Study Phase: Phase 2
View 9 Less Clinical Trials

274 Total Publications

Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.
Journal: The New England journal of medicine
Published: November 19, 2025

Frequently Asked Questions about Mariano P. Provencio

Is Mariano P. Provencio a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Mariano P. Provencio is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mariano P. Provencio participate in research or clinical trials?

Yes. Mariano P. Provencio has published 274 articles and abstracts on conditions like Lung Cancer. You can view a list of Mariano P. Provencio's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Provencio's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile